Trial
NCT03578198
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Seoul National University Hospital
Collaborators
Hallym University Medical Center; Kyunghee University Medical Center; Gyeongsang National University Hospital
Condition
CD20-positive Non-Hodgkin Lymphoma
Intervention
Rituximab + MG4101
Why stopped
Issues in supply of IP
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-27